title: Accelerated streptokinase--a new thrombolytic regimen in acute myocardial infarction.
abstract: Efficiency and safety of an accelerated regimen of streptokinase (1.5 M.U. over 20 min., 109 patients) has been compared with the standard regimen (1.5 M.U. over 60 min, 119 patients) in 218 patients admitted within the first 6 hours after the onset of the symptoms of acute myocardial infarction. Using the noninvasive criteria we found a coronary reperfusion rate of 77.04% in patients belonging to the accelerated regimen group and this value was significantly higher than the one of 57.14% registered in the standard group. No major hemorrhagic events were registered in both groups. Although the hypotension appeared to be more frequent in patients in whom the accelerated regimen was used, however this side effect proved to be transient and well controlled using the rapid infusion of natrium chloride solution. In conclusion, the accelerated regimen of streptokinase is safe and followed by a higher rate of coronary reperfusion as compared to the standard one.
authors.affiliation: Department of Internal Medicine and Cardiology, Floreasca Emergency Hospital, Bucharest, Romania.
authors.forename: G
authors.initials: G
authors.lastname: Tatu-Chiţoiu
authors.forename: C
authors.initials: C
authors.lastname: Teodorescu
authors.forename: A
authors.initials: A
authors.lastname: Flueraşu
authors.forename: P
authors.initials: P
authors.lastname: Căpraru
authors.forename: M
authors.initials: M
authors.lastname: Guran
authors.forename: M
authors.initials: M
authors.lastname: Dan
authors.forename: V
authors.initials: V
authors.lastname: Chioncel
authors.forename: A
authors.initials: A
authors.lastname: Bumbu
authors.forename: S
authors.initials: S
authors.lastname: Cornaciu
mesh_terms: D000368:Aged; D001241:Aspirin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D004562:Electrocardiography / Q000187:drug effects; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy*; D013300:Streptokinase / Q000008:administration & dosage* / Q000009:adverse effects; D015912:Thrombolytic Therapy / Q000009:adverse effects / Q000379:methods* / Q000706:statistics & numerical data; D013997:Time Factors
chemical_list: D005343:Fibrinolytic Agents; D013300:Streptokinase; D001241:Aspirin